GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2009

Pfizer to Extend Use of Patient Selection Technology from Monogram

Pfizer to Extend Use of Patient Selection Technology from Monogram

Pfizer extends collaboration with Monogram for HIV treatment

  • Pfizer will continue its collaboration with Monogram Biosciences through December 31, 2010, to use the Trofile assay developed by Monogram to help select patients for a Pfizer anti-HIV medication.

    The agreement will be extended to allow Monogram's assay to be used to help find patients who may benefit from Selzentry, and may be continued on a year-by-year basis until December 2014.

    "The adjustments to our collaboration with Pfizer strengthen the platform for commercialization of Trofile and indicate Pfizer’s ongoing support for Trofile, which is the clinically validated method of selecting patients for CCR5 antagonists such as Selzentry," says William Young, Monogram CEO. "We are pleased to be continuing our collaboration with Pfizer outside of the U.S."

    The screening technology may also be used in the new entity created by Pfizer in its joint collaboration with Glaxosmithkline, Monogram reports, after new language in the agreement assigned rights to the assay to the merger.

    Selzentry is a second-line treatment designed to reduce the amount of HIV infection by blocking the CCR5 receptor, according to Pfizer. Patients are asked to take a blood test given by their doctors to see whether they have the CCR5-trophic variant of the virus.ADNFCR-2184-ID-19174312-ADNFCR



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?